We are recalling two batches of Children’s Panadol 5-12 Suspension Strawberry (200mL) and one batch of Children’s Panadol 5-12 Suspension Orange (200mL)
These press releases are intended for business journalists and analysts/investors
GlaxoSmithKline (GSK) Australia has reported its 2015 results to the Australian Securities and Investment Commission (ASIC) for its pharmaceuticals and vaccines business, as well as GSK Consumer Healthcare (a joint venture with Novartis) and ViiV (a joint venture with Pfizer and Shionogi focused on HIV).
In 2015, GSK Australia made payments totalling $3.6 million to healthcare professionals (HCPs) and health-related organisations (HCOs) for grants, sponsorships and consultancy fees related to chairing and speaking at meetings, assistance with training and participation in advisory boards.
GSK advises of a temporary disruption to the supply of Bactroban products
GSK has responded to the state of emergency declared in Fiji by providing funding and urgent supplies of medicine.
GSK supports National Immunisation Program (NIP) with additional whooping cough protection via an 18-month dose on the NIP
GSK Australia is proud to be partnering with the Australian Government to re-introduce a diphtheria, tetanus, acellular pertussis (DTPa) vaccine on the National Immunisation Program for children at 18-months of age.
New research conducted on behalf of Voltaren and GSK Consumer Healthcare shows that 97 percent of Australians suffer from body aches, with a massive two thirds (68%) experiencing it at least weekly, higher than the other 13 countries included in the survey. Findings show pain impacts our social life, love life, performance at work and ability to parent.
GSK has launched a new immunology research collaboration model – the Immunology Catalyst sabbatical program – designed to embed academic scientists in GSK laboratories with the goal to broaden scientific insight and drive major breakthroughs in applied immunology.
Australian Professor John Hamilton from the University of Melbourne was the first academic to join the program.
GSK prioritises whooping cough vaccine availability for those most at risk of the disease and confirms uninterrupted supply of Boostrix® to all Australian State, Territory and Federal Government vaccination programs where Boostrix is the vaccine of choice.
We are one of the world’s largest science-led pharmaceutical and healthcare companies. Each year we research, manufacture and sell innovative medicines, vaccines and healthcare products for millions of people across the world, helping them to do more, feel better and live longer.